NEW YORK (GenomeWeb) – Hologic announced after the close of the market on Wednesday that it will sell its share of a blood screening business to Grifols, its commercial partner, in a deal worth $1.85 billion in cash.

The boards of directors of both companies have approved the deal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.